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Word count: 169 
Lipooligosaccharide is an integral component of the Campylobacter cell membrane with a  structure of  core oligosaccharides 
forming inner and outer core regions and a lipid A moiety. The gene content of the lipooligosaccharide core biosynthesis cluster 
exhibits extensive sequence variation which leads to the production of variable cell surface lipooligosaccharide structures in 
Campylobacter. Some lipooligosaccharide outer core molecules in Campylobacter jejuni are molecular mimics of  host structures 
(such as  neuronal gangliosides) and are thought to  trigger neuronal disorders (particularly Guillain-Barré Syndrome and Miller  
Fisher Syndrome) in humans. The extensive genetic variation in the LOS biosynthesis gene cluster, a  majority of  which occurs in  
the lipooligosaccharide outer core biosynthesis gene content present between lgtF and waaV, has led to the development of a 
classification system with 23 classes (A-W) and four groups (1-4) for  the  Campylobacter jejuni lipooligosaccharide region. This  
review presents an updated and simplified classification system for LOS typing alongside an overview of the frequency of 
Campylobacter jejuni lipooligosaccharide biosynthesis genotypes and structures in various Campylobacter jejuni populations. 
 
Contribution to the field 
 
Campylobacter jejuni is an important food borne pathogen and  isolates can  be  obtained from several environmental and  clinical 
sources (i.e. poultry, Guillian Barré Syndrome cases, and enteritis patients). The cell surface lipooligosaccharide (LOS) is important      
for pathogenicity and is encoded by a complex biosynthesis cluster resulting in highly variable LOS structures. LOS genotypes vary 
geographically and by clinical and environmental source. In  this review, we  summarise data from literature relevant to  the 
distribution of C. jejuni LOS locus genotypes in various geographical areas and sources to  present an  up  to  date picture of  C.  jejuni 
LOS genotype predominance, which has important implications in vaccine design. To better understand the complexity of the LOS 
biosynthesis locus, we  propose an  updated system whereby novel LOS  classes can  be  assigned into the  four pre-established LOS 
groups. This updated and simplified classification system will help researchers to investigate increasingly complex levels of  C.  jejuni 
LOS variation as novel classes are identified. 
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16 Lipooligosaccharide is an integral component of the Campylobacter cell membrane with a structure of 
17 core oligosaccharides forming inner and outer core regions and a lipid A moiety. The gene content of 
18 the lipooligosaccharide core biosynthesis cluster exhibits extensive sequence variation which leads to 
19 the production of variable cell surface lipooligosaccharide structures in Campylobacter. Some 
20 lipooligosaccharide outer core molecules in Campylobacter jejuni are molecular mimics of host 
21 structures (such as neuronal gangliosides) and are thought to trigger neuronal disorders (particularly 
22 Guillain-Barré Syndrome and Miller Fisher Syndrome) in humans. The extensive genetic variation in 
23 the LOS biosynthesis gene cluster, a majority of which occurs in the lipooligosaccharide outer core 
24 biosynthesis gene content present between lgtF and waaV, has led to the development of a classification 
25 system with 23 classes (A-W) and four groups (1-4) for the Campylobacter jejuni lipooligosaccharide 
26 region. This review presents an updated and simplified classification system for LOS typing alongside 
27 an overview of the frequency of Campylobacter jejuni lipooligosaccharide biosynthesis genotypes and 
















35 1. Introduction 
36 Campylobacter is a foodborne enteropathogen which causes an acute, self-limiting gastroenteritis in 
37 humans with various non-specific symptoms including watery or bloody diarrhoea, abdominal pain, 
38 headache, fever, chills, and dysentery (van Spreeuwel et al., 1985; Black et al., 1988; Perkins and 
39 Newstead, 1994). The annual estimated number for Campylobacter infection is 96 million worldwide 
40 (Havelaar et al., 2015). Campylobacter infection occurs in adults and children in developing countries 
41 and can also lead to death in young children (Janseen et al., 2008). In some cases, there can also be 
42 long-term, post-infection consequences of Campylobacter infection such as the neuronal disorders 
43 Guillain-Barré Syndrome (GBS) and Miller Fisher Syndrome (MFS), Reiter’s arthritis, and irritable 
44 bowel syndrome (IBS) (Endtz et al., 2000; McCarthy and Giesecke, 2001). Cohort studies on 
45 confirmed Campylobacter cases estimate that GBS develops following infection in anywhere from 21 
46 to 172 per 100,000 Campylobacter cases and that this rate is approximately 100-fold higher than in 
47 the general population (McCarthy and Giesecke, 2001; Tam et al., 2006; Scallan Walter et al., 2019). 
48 Case control studies on patients diagnosed with GBS repeatedly show a significant association with 
49 Campylobacter, with an average rate of infection of 35.4 % compared with 4.4% in controls 
50 (Poropatich et al. 2010). A recent systematic review of all factors contributing to the development of 
51 GBS concluded that Campylobacter infection was the most common trigger of the disease with a 
52 substantial evidence base (Wachira et al. 2019). 
 
53 Campylobacter species, similar to Neisseria and Haemophilus, lack LPS in the outer-cell membrane 
54 and instead possess lipooligosaccharide (LOS) which comprises of lipid A and core structures 
55 (Mandrell  et al., 1992;  Moran, 1997; Duncan  et  al., 2009).  In  comparison to  LPS,  LOS are low- 
56 molecular weight biological molecules lacking O-chains (Moran, 1997). Other Campylobacter cell- 
57 surface structures include capsular polysaccharides (CPS), O-linked glycosylated flagellum, and N- 
58 linked glycoproteins. LOS, CPS, and O-linked glycans (mainly flagellar glycans) are variable among 
59 different strains, whilst N-linked glycoproteins remain conserved (Szymanski et al., 2003; Karlyshev 
60 et al., 2005; Day et al., 2012). The glycome which comprises these four types of carbohydrates 
61 containing conjugate molecules is synthesised by more than 8% of the genome in Campylobacter 
62 jejuni 11168 (Parkhill et al., 2000; Gundogdu et al., 2007). 
63 
64 No commercial vaccine has been developed for Campylobacter to date and this is largely due to the 
65 versatile and diverse nature of Campylobacter physiology and genomics (Riddle and Guerry, 2016). 
66 Subunit vaccines formed with flagellum-secreted proteins (C. jejuni 81-176 FlaC, C. jejuni 81-176 
67 FspA1, and C. jejuni CG8486 FspA2) and recombinant protein (ACE 393) have been experimentally 
68 tested in mice and healthy volunteers, respectively, but no promising candidates for human vaccines 
69 have been identified (Baqar et al., 2008; Poly et al., 2019). Glycoconjugate vaccines such as C. jejuni 
70 81-176 conjugated CPS vaccine (CRM-197) has been tested in monkeys but remained unsuccessful 
71 as it did not provide adequate immunity (Monteiro et al., 2009). A conjugated LOS vaccine has not 
72 been investigated yet for C. jejuni, however, LOS of two C. jejuni strains BH-01-0142 and CG8421 
73 may be considered and utilised for vaccine development (Poly et al., 2008, 2018). LOS functions as a 
74 virulence determinant, immune modulator and essential survival element which make it a potential 
75 glycoconjugate vaccine candidate. However, prevalence of diverse LOS genotypes (due to  variation 
76 within the gene content of LOS biosynthesis gene cluster) and presence of phase variation (a 
77 phenomenon where gene on/off switching varies the cell-surface LOS structures and functions) within 
78 the LOS biosynthesis genes are the two main features which make LOS less desirable as a vaccine 
79 candidate (Guerry et al., 2002; Gilbert et al., 2002; Parker et al., 2005, 2008). Furthermore, it is unclear 
80 how LOS genotypes are reflected in overall LOS biosynthetic structures. The prevalence of LOS 
81 genotypes vary from geographic region to region while phase variation varies from strain to strain, 





82 and both types of LOS locus variation need to be investigated for vaccine design. The most prevalent 
83 LOS genotypes circulating regionally must be taken into account for maximal efficiency of LOS 
84 conjugated vaccine and therefore the frequency of C. jejuni LOS genotypes in different countries 
85 including USA, UK, Netherlands, France, Belgium, Finland, Sweden, Japan and Bangladesh has been 
86 investigated previously (Godschalk et al., 2004; Parker et al., 2005; Quinones et al., 2007; Habib et 
87 al., 2009; Ellström et al., 2013, 2014, 2016; Islam et al., 2014; Ohishi et al., 2017; Islam et al., 2018; 
88 Elhadidy et al., 2018; Thépault et al., 2018). In this review, data from literature relevant to the 
89 distribution of C. jejuni LOS locus genotypes in various geographical areas of world will be analysed 
90 to present an up to date picture of C. jejuni LOS genotype predominance, which may be important in 
91 vaccine design. This review also presents an updated and simplified classification system for the LOS 
92 biosynthesis  locus  to  aid  fellow  researchers  investigating  increasingly  complex  levels  of  LOS 
93 variation and the role it plays in Campylobacter infection. 
94 
95 2. Campylobacter LOS as a virulence determinant 
 
96 LOS in Campylobacter does not only maintain the integrity of the cell membrane structure, but also 
97 acts as a barrier for those molecules which are transported through the cell membrane (Karlyshev et 
98 al., 2005). Deletion of LOS core in C. jejuni 11168 does not seem essential for viability (Marsden et 
99 al., 2009), but truncation of LOS can be lethal in C. jejuni strains other than 11168 (Phongsisay et al., 
100 2007). For example, antibiotic permeability into the cell increases due to alteration in LOS structures, 
101 possibly because LOS structural changes decrease the cell membrane hydrophobicity. This is the 
102 reason that mutants of C. jejuni LOS genes are highly susceptible to some antibiotics, specifically to 
103 erythromycin (Kanipes et al., 2004; Jeon and Zhang, 2009; Marsden et al., 2009). In addition to 
104 providing a barrier to antibiotics, LOS also confers resistance to Campylobacter cells against human 
105 serum proteins including α-defensins, cathelicidins and bactericidal/permeability-increasing proteins 
106 (Marsden et al., 2009; Keo et al., 2011). DNA uptake into a bacterial cell is an outer cell membrane- 
107 dependent  process.  Therefore,   LOS  modification  in  the  outer  cell  membrane  may   also  affect 
108 Campylobacter’s ability to uptake foreign DNA or its characteristic of natural transformation (Jeon 
109 and Zhang, 2009; Marsden et al., 2009). Mutants of Campylobacter LOS genes, in comparison to their 
110 respective WT strains, have showed reduced adherence and invasion into host intestinal epithelial cells 
111 (Fry et al., 2000; Kanipes et al., 2004; Javed et al., 2012), which might be due to reduced interaction 
112 between host cell receptors and altered LOS structures. A caveat to these studies is that deletion of 
113 LOS biosynthesis genes or drastic changes in LOS structure may have a general destabilizing effect on 
114 the LOS. A mutant of C. jejuni 11168, lacking the core oligosaccharides in its LOS structures, was 
115 unable to invade Caco-2 cells, indicating the importance of LOS in Campylobacter invasion into host 
116 cells (Marsden et al., 2009). C. jejuni strains with sialylated LOS showed higher potential of adhesion, 
117 invasion and translocation than those with non-sialylated LOS (Louwen et al., 2012). Two sialic acid 
118 biosynthesis genes (cgtB and wlaN) were found commonly present in highly invasive C. jejuni strains 
119 (Müller et al., 2007) and mutation of a sialic acid biosynthesis gene, cstII, in a C. jejuni strain  caused 
120 reduction in its invasion into epithelial cells (Louwen et al., 2008), supporting the role of LOS 
121 sialylation or sialic acid biosynthesis genes in C. jejuni invasion. However, C. jejuni mutants of other 
122 LOS biosynthesis genes (waaC and cj1136) also showed significant reduction in invasion into 
123 intestinal epithelial cells (Kanipes et al., 2008; Javed et al., 2012). Furthermore, only 23% of C. jejuni 
124 isolates from blood borne infection or truly invasive strains contained sialic acid biosynthesis genes 
125 (Ellström et al., 2014). These studies indicate that not only sialic acid biosynthesis genes, but the overall 
126 presentation of LOS structure, plays an important role in adherence and invasion of C. jejuni into host 
127 cells. Complete cell-surface LOS structures in C. jejuni are also important for optimum colonization 
128 of chick caeca and this is linked to the increased hydrophobicity and susceptibility to bile of LOS 





129 mutants (Iwata et al., 2013). Thus, LOS is an important virulence determinant in C. jejuni. ., 2012). It 
130 may also be the case that since C. jejuni LOS are densely present on the cell surfaces and they are 
131 readily available to stimulate and interact with human immune cells such as macrophages , LOS could 
132 also contribute to the binding of other cell types.. For example, the C. jejuni LOS terminal N-acetyl 
133 galactosamine residues bind to the human macrophage galactose-type lectin receptors (van Sorge et 
134 al., 2009). LOS containing sialic acid residues have particular significance for human disease due to 
135 their increased ability to bind to immune cells and their similarity to neuronal structures. C. jejuni LOS 
136 sialic acid residues bind to TLR-4 and sialoadhesin receptors present on the human macrophage cell 
137 surfaces (Klaas et al., 2012; Heikema et al., 2013; Stephenson et al., 2013). C. jejuni LOS sialic acid 
138 residues are also ligands of Sialic-acid binding immunoglobulin-like lectins present on human 
139 monocytes and natural killer cells (Avril et al., 2006). The LOS structures with variable epitopes 
140 presented on different C. jejuni cell surfaces can also mimic human neuronal gangliosides. For this 
141 reason, antibodies produced against the LOS structural epitopes do not only bind to LOS structures, 
142 but also to human neuronal gangliosides. The cross-reactivity of anti-LOS antibodies with human 
143 gangliosides leads to the development of neuronal disorders (GBS and MFS) in humans (Yuki et al., 
144 1997; Nachamkin et al., 1998; Endtz et al., 2000; McCarthy and Giesecke, 2001; Wakerley and Yuki, 
145 2015). This is evident by the development of pathological changes in peripheral nerves and weakness 
146 in the limbs as well as production of anti-GM1 antibodies in rabbits upon sensitisation with C. jejuni 
147 LOS (Yuki et al., 2004). Further, knockout mutants of C. jejuni sialic acid biosynthesis genes (orf10 
148 and cst-II) with truncated and non-sialylated LOS structures show reduced reactivity with GBS patient 
149 serum. In addition, administration of these mutated LOS structures into mice did not induce anti- 
150 ganglioside antibody responses (Godschalk et al., 2008). The allelic variation in the cst-II gene leads 
151 to the expression of either threonine (Thr) or asparagine (Asn) at position 51 of the sialyltransferase 
152 (Gilbert et al., 2002). This genetic polymorphism (and change in host-mimicking ganglioside epitopes) 
153 can further affect the development of autoimmune and clinical symptoms of GBS, supporting the role 
154 of LOS gene variations in GBS (Koga et al., 2005). In GBS, the cranial nerves extending from the 
155 brain to various areas of the head and neck are affected, which further develop difficulty in walking, 
156 muscle weakness, and muscle pain, whilst MFS, a variant of GBS, is characterised mainly by paralysis 
157 of eye muscles and problems with balance and coordination (Nachamkin et al., 1998). These post- 
158 infection complications are infrequent and typically appear in immune compromised individuals, such 
159 as individuals with HIV infection (McCarthy and Giesecke, 2001; Janseen et al., 2008). They do not 
160 develop solely as a consequence of Campylobacter infection and other bacterial or host specific risk 
161 factors  aid  in  stimulating  the  production  of  anti-ganglioside  antibodies  (Figure  1)  (Revez  and 
162 Hänninen, 2012; Islam et al., 2014). This varies among C. jejuni strains and Campylobacter infected 
163 individuals and contributes to a complex picture of GBS development and progression post-infection 
164 (Müller et al., 2007; Godschalk et al., 2007). Some C. jejuni strains do not produce ganglioside 
165 mimicking LOS structures at all despite the presence of sialic acid biosynthesis genes and therefore, 
166 the presence of sialylated LOS biosynthesis genes do not always correspond with the C. jejuni potential 
167 for neural disease development (Houliston et al., 2011). 
168 
169 3. The LOS biosynthesis locus in C. jejuni 
170 In proposing a new classification for the LOS, it is important to appreciate the complexity of the LOS 
171 biosynthesis loci that has informed rationale for current and historic classification systems. The LOS 
172 lipid A backbone in C. jejuni contains a 3-diamino-2, 3-dideoxy-D-glucopyranose linked to 2-amino- 
173 2-deoxy-D-glucose (GlcN), whereas the C. coli lipid A backbone consists of two GlcN (Culebro et al., 
174 2016). The lipid A backbone in most of the Campylobacter strains is linked to 6 acyl chains (2 





175 hydroxyl-linked and 4 amide-linked) (Moran, 1997). The LOS core biosynthesis in C. jejuni is 
176 achieved at the genetic level by a cluster of LOS biosynthesis genes (Figure 2). Each LOS biosynthesis 
177 gene produces an individual enzyme involved in either monosaccharide biosynthesis or addition of a 
178 particular monosaccharide to the LOS structure (Karlyshev et al., 2005; Parker et al., 2005, 2008; Iwata 
179 et al., 2013). The inner core of C. jejuni LOS has two heptose and two glucose units (Klena et al., 1998; 
180 Gilbert et al., 2002; Kanipes et al., 2004, 2006). The Heptosyltransferase-I (waaC) adds the first 
181 heptose (Hep-I) to KDO (3-deoxy-D-manno-octulosonic acid). Heptosyltransferase-II (waaF) 
182 catalyses the addition of a second heptose (Hep-II) to Hep-I (Klena et al., 1998; Kanipes et al., 2004, 
183 2006). In C. jejuni (strain 11168) Hep-1 and Hep-II are synthesised and added to the inner core of LOS 
184 by the phosphoheptose isomerase (gmhA), a D-glycero-beta- D-manno-heptose-7-phosphate kinase 
185 (waaE), an ADP-L-glycero-D-manno-heptose-6-epimerase (waaD), and a dephosphatase (gmhB) 
186 (Karlyshev et al., 2005; Iwata et al., 2013).Unlike the inner core, the outer core of LOS varies 
187 extensively among C. jejuni strains (Linton et al., 2000; Godschalk et al., 2004; Houliston et al., 2011). 
188 The outer core of C. jejuni 11168 is synthesised by glycosyltransferases [cj1136 (ORF4), cj1137 
189 (ORF14), and cj1138 (ORF15)], N-acetyl galactosaminyl transferase [cgtA/neuA1 (ORF5/10)], 
190 sialyltransferase [cst-III (ORF7)], and galactosyltransferase (wlaN) and is illustrated as an example in 
191 Figure 2 (Gilbert et al., 2000; Linton et al., 2000; Gilbert et al., 2002; Guerry et al., 2002; Karlyshev 
192 et al., 2005; Javed  et al., 2012).  In  addition to  core synthesis,  a LOS biosynthesis  gene (waaM)  is 
193 located in the cluster that encodes an enzyme (lipid A biosynthesis lauroyl acyltransferase) to catalyse 
194 the addition of a KDO molecule to the backbone of lipid A (Karlyshev et al., 2005). Campylobacter 
195 LOS structures are synthesised in the cytoplasmic side of the inner cell membrane from where they are 
196 flipped to the periplasmic side of the inner cell membrane and finally, are integrated into the outer cell 
197 membrane (Whitfield and Trent, 2014; Simpson et al., 2015). Based on similarities to 
198 lipopolysaccharide assembly machinery in E. coli, it is predicted that N-linked glycosylation 
199 glycosyltransferase (wlaM/pglG) and flippase (wlaB/pglK) can respectively facilitate cytoplasm-to- 
200 periplasm LOS flipping and periplasm-to-outer cell membrane LOS translocation in Campylobacter 




203 4. Variation in C. jejuni LOS biosynthesis locus 
 
204 The variation in the C. jejuni LOS biosynthesis gene region occurs either due to (i) mutations within 
205 the nucleotides of LOS biosynthesis gene sequences or (ii) recombination between LOS biosynthesis 
206 gene/gene regions. 
207 
 
208 4.1. Variation at the nucleotide level 
 
209 Nucleotide level variations within the LOS biosynthesis genes can occur due to phase variation, where 
210 slip strand mispairing during replication of homopolymeric tracts can lead to insertions or deletions of 
211 single bases (Gilbert et al., 2002). The LOS gene wlaN in C. jejuni 11168, C. jejuni 331 and C. jejuni 
212 2500 containing a homopolymeric tract of 8G produces the fully transcribed and functional gene 
213 product β 1, 3-galactosyltransferase (Linton et al., 2000; Müller et al., 2007; Semchenko et al., 2012). 
214 A variant in these strains containing a 9G homopolymeric tract in wlaN results in a frameshift mutation 
215 and premature translational termination with a non-functional gene product, which cannot add the 
216 terminal galactose in the LOS structure, and consequently converts a GM1-like LOS epitope into a 
217 GM2 mimic (Linton et al., 2000; Semchenko et al., 2012). Site-directed mutagenesis of the 
218 homopolymeric tract in C. jejuni 11168 wlaN from 8G to 11G increases the rate of phase variation ~10 





219 fold in this gene, and in general the rate of phase variation increases with longer tract lengths in multiple 
220 genes (Bayliss et al., 2012). Phase variation of C. jejuni 11168 wlaN was not observed in vivo during 
221 colonization of chickens aged 2-4 weeks, but an increase in tract length from 8G to 9G to switch off 
222 expression of wlaN was detected after passage of C. jejuni 224 and 331 in 5 day old chicks, with C. 
223 jejuni 11168-O remaining unchanged (Bayliss et al., 2012, Semchenko et al., 2012). In the same study, 
224 C. jejuni 331 switched off wlaN after co-culture with the intestinal cell line CaCo-2 and C. jejuni 224 
225 switched off expression of the LOS genes Cj1144-45 after colonizing chicks, giving further evidence 
226 that strain-specific and host-specific factors can both influence phase variation of LOS genes 
227 (Semchenko et al., 2012). Phase variation in a number of other LOS biosynthesis genes has been 
228 observed at both the genotype and phenotype level in multiple strains including cst-II, cgtA, cgtD, 
229 ORF23 and ORF25 (Guerry et al., 2002, Parker et al., 2005, Godschalk et al., 2006, 2007, Houliston 
230 et al., 2011, Wanford et al., 2018). Multiple combinations of phase variable genes can also lead to 
231 novel LOS structures. Different combinations of on and off phenotypes in C. jejuni (strain GC149) are 
232 encoded by the cgtA and cgtD outer core glycosyltransferases and result in structural molecular mimics 
233 of either GD3 (cgtA off), GT1a (cgtA on/cgtD off) or ganglio/Pk (cgtA on/cgtD on) gangliosides 
234 (Houliston et al., 2011).. Phase variation of LOS genes can therefore lead to mixed populations of 
235 LOS gene variants and increase the diversity of LOS structural epitopes within a single strain of 
236 Campylobacter. (Guerry et al., 2002). 
237 
238 Sequence variation may also occur due to single nucleotide mutations, which can inactivate the LOS 
239 biosynthesis genes without involving the phenomenon of phase variation. For example, deletion of an 
240 A-base at position 1234 in lgtF (a LOS biosynthesis gene) alters the catalytic activity of its encoded 
241 enzyme, glycosyltransferase, in four C. jejuni strains (ATCC 43432, ATCC 43446, OH4382, and 
242 OH4384). As a result, the produced glycosyltransferase does not have the potential to catalyse the 
243 addition of ß-1, 2-glucose to Heptose-II during the LOS synthesis. Similarly, the base substitution of 
244 the final base in Orf5/10 (cgtA/neuA1) in C. jejuni ATCC 43430 changes the amino acid (cysteine 
245 tyrosine) which further leads to the production of a non-functional enzyme (Gilbert et al., 2002). The 
246 LOS gene, cgtA, with missing A-base at position 71 substitutes one amino acid in the cgtA encoding 
247 enzyme, N-acetyl galactosaminyl transferase, which further leads to the inactivation of N-acetyl 
248 galactosaminyl transferase in C. jejuni OH4382 and OH4384 and truncates the LOS structure (Gilbert 
249 et al., 2002). Similarly, a five base deletion from the cst-III gene of C. jejuni GB1 alters the number of 
250 amino acids (294  219) in sialyltransferase and eventually produces a non-sialylated LOS (Godschalk 
251 et al., 2007). 
 
252 4.2. Variation at allele or gene level and LOS locus classes in C. jejuni 
253 In recent years an alphabetical system of class organization for LOS genes within the C. jejuni LOS 
254 biosynthesis locus has been developed based on 23 C. jejuni LOS classes (A through W) which have 
255 been previously described (Gilbert et al., 2002; Parker et al., 2008; Richards et al., 2013). An insertion 
256 or deletion of a LOS biosynthesis gene or gene regions into the LOS locus can give rise to a different 
257 class type (Parker et al., 2005, 2008). Alterations of portions of the LOS biosynthesis genes or different 
258 alleles can also establish a new class or subclass, for example allele variation in cgtA and wlaN genes 
259 generates A and B subclasses including A1, A2, B1, B2 (Parker et al., 2005). In addition, disruption in 
260 resident LOS biosynthesis genes can also form a new class, for instance, disruption in class E ORF26 
261 establishes the LOS locus class P (Parker et al., 2005). The developed new locus type can be variable 
262 both in gene content and gene organisation (Parker et al., 2005; Revez and Hänninen, 2012). C. jejuni 
263 acquires new genes in its LOS biosynthesis region by horizontal gene transfer. The horizontal transfer 
264 of LOS biosynthesis genes from C. jejuni O4 (GM1 strain) to C. jejuni 81116 (non-GM1 strain) 
265 changed it into a GM1-like LOS producing strain (Phongsisay et al., 2006). Similarly, a C. jejuni GB11 





266 strain possessing class C locus acquired a class A locus, identical to the LOS locus of C. jejuni ATCC 
267 43446, whilst retaining the same sequence in the remainder of the genome (Gilbert et al., 2004). 
268 
269 Variation in LOS biosynthesis gene alleles causes alterations in the LOS structure. For instance, two 
270 cst-II gene alleles lead to the expression of either threonine (Thr) or asparagine (Asn) at position 51 of 
271 the  translated  enzyme.  As  a  result,  the  enzyme  retains  either  a  monofunctional  (Thr     2,   3- 
272 sialyltransferase activity) or a bifunctional (Asn  2, 3- and 2, 8-sialyltransferase) activity and produces 
273 LOS with one and two sialic acids respectively (Gilbert et al., 2002). Variation in LOS locus gene 
274 content can vary the carbohydrate content, linkages between the carbohydrate units, and core length in 
275 cell-surface LOS structures (Guerry et al., 2002; Gilbert et al., 2002). Variation in LOS locus gene 
276 content as well as in its gene organisation varies the cell-surface LOS structurally and functionally. It 
277 is not always the case that LOS structures belonging to the same LOS locus type encode similar 
278 epitopes. C. jejuni 11168 and 520, both belong to class C, but C. jejuni 520 can produce a wider variety 
279 of human ganglioside mimics than C. jejuni 11168 (Semchenko et al., 2012). C. jejuni strains that 
280 contain a type A LOS locus frequently encode and express human ganglioside mimics on bacterial cell 
281 surfaces which include GM1a, GM1b, GD1a, and GD1b (Nachamkin et al., 2002; Godschalk et al., 
282 2004; Mortensen et al., 2009). For example, there is a GM1-like mimic in C. jejuni 11168 (class C), a 
283 GQ1b-like mimic in C. jejuni 81-176 (Class B), a Lewis type I-like mimic in C. jejuni RM1503 (class 
284 M), and a paragloboside/Pk like antigens in C. jejuni RM1221 (class F) (Godschalk et al., 2004; 
285 Mortensen et al., 2009; Houliston et al., 2011). C. jejuni GC149 (class R) contains sialic acid 
286 biosynthesis genes and may present ganglioside like mimics (GT1a, GD3) as well as a hybrid form of 
287 ganglio and P-type antigens (Parker et al., 2008; Houliston et al., 2011). Other LOS classes such as D 
288 and E also possess human ganglioside-like LOS structures, but these are different to GM1, GD1 and 
289 GQ1b  (Godschalk  et  al.,  2004).  Class  P  LOS  have  a  lack  of  sialic  acid  and  possess  N-acetyl 
290 quinovosamine instead (Poly et al., 2008). The variable LOS structural epitopes presented by different 
291 C. jejuni LOS locus types are demonstrated in Table 1. 
292 
293 The expression of variable cell surface LOS structures and mimicry with human blood antigen 
294 glycosphingolipids or neuronal ganglioside glycosphingolipids as a consequence of gene variation  in 
295 the LOS locus in C. jejuni is an important virulence factor and may have a direct link to the progression 
296 of specific neuronal disorders post-infection (Ang et al., 2002; Mὓller et al., 2007; Houliston et al., 
297 2011; Semchenko et al., 2012). For example, C. jejuni strains with LOS locus class A and variable 
298 human ganglioside mimics (GM1a, GM1b, GD1a, and GD1b) trigger GBS in Campylobacter infected 
299 patients (Nachamkin et al., 2002; Godschalk et al., 2004, 2007; Mortensen et al., 2009). Whereas, C. 
300 jejuni strains with LOS class B and corresponding GQ1b-like LOS structures are likely to develop 
301 MFS in Campylobacter infected patients (Godschalk et al., 2007; Islam et al., 2014). Genetic diversity 
302 within the LOS locus plays an important role in the development of post-infection effects, however, 
303 this does not have any association with acute-phase symptoms such as diarrhoea or abdominal pain 
304 (Poly et al., 2008; Mortensen et al., 2009; Ellström et al., 2013). This indicates that LOS sialylation is 
305 not required for human diarrheal disease and that both the sialylated and non- sialylated LOS can be 
306 used for vaccine design (Poly et al., 2008, 2018). 
307 
308 5. Simplification of C. jejuni LOS locus classification 
309 LOS classes A-H were initially described (Gilbert et al., 2002; Parker et al., 2005) and these known C. 
310 jejuni LOS classes were then primarily categorised into four groups and included LOS classes A, B 
311 and C belonging to a Group 1, LOS class E in Group 2, LOS class D and F in Group 3, and LOS class 
312 G in Group 4 (Karlyshev et al., 2005). Later, Parker et al. (2008) identified 11 more C. jejuni LOS 
313 classes including I-S. Subsequently, Richards et al. (2013) identified C. jejuni strains with novel LOS 





314 loci and established 4 more LOS classes including T, U, V and W. The novel LOS loci identified in 
315 the latter two studies have never been assigned to the LOS groups. To better understand the prevalence 
316 of C. jejuni LOS groups and groups related to LOS classes, we propose a simplified LOS classification 
317 system (Figure 3) where various already known LOS classes have been assigned into the pre- 
318 established LOS groups (Karlyshev et al., 2005) on the basis of sharing similar LOS biosynthesis gene 
319 content. Group 1 includes all the LOS locus types (A, B, C, R, M and V) which contain genes for sialic 
320 acid synthesis and translocation (ORF7/cstII/cstIII, ORF8/neuB1, ORF9/neuC1 and ORF10/neuA1) 
321 whereas the other three groups have LOS loci with no sialic acid biosynthesis genes. Based on sequence 
322 similarity of LOS loci H, O, P and W to locus E (ORF21 to ORF34), these four classes are now assigned 
323 to group 2. Furthermore, K, Q, N, I, J, and S sharing ORF17, ORF18/cgtH, ORF19/cgtG, and 
324 ORF20/cgtE are assigned to LOS group 3 and L, G, T, and U sharing ORF36, ORF37 and ORF38 are 
325 assigned to LOS group 4 classes. 
 
326 6. Prevalence of C. jejuni LOS locus classes and groups 
327 A large number of available C. jejuni genomes with metadata has been deposited in recent years and 
328 has the potential to provide a full and comprehensive overview of the frequency of C. jejuni LOS 
329 genotypes in C. jejuni populations (from different isolation sources and various clonal complexes). 
330 However, much of this data remains unpublished and should be a focus of ongoing efforts. However, 
331 analysis of previously published studies examining the frequencies of C. jejuni LOS locus classes and 
332 groups present in enteritis, GBS, blood borne infection, and poultry associated C. jejuni populations 
333 indicates that the hierarchy of LOS group (Group 1 > Group 2 > Group 3 > Group 4) is largely 
334 conserved amongst human and poultry derived C. jejuni isolates (Figure 4). This also indicates that the 
335 B and C LOS classes in clinical enteric disease and LOS class A in GBS associated C. jejuni 
336 populations are found to be highly predominant. In comparison to the high prevalence of LOS class C 
337 (42%) in clinical isolates in Sweden (Ellström et al., 2016), a very small number of clinical strains 
338 (2%) in Bangladesh had association with LOS locus C (Islam et al., 2018), suggesting that C. jejuni 
339 LOS class distribution may vary geographically. Further, when comparing the combined frequency of 
340 LOS ABC types in different populations of C. jejuni isolates (clinical, enteritis and poultry), 
341 approximately 50–75% of strains in all C. jejuni populations belong to LOS classes A, B or C. The 
342 only exception to these results was data from Ellström et al., 2014 where C. jejuni were isolated from 
343 human blood-borne infections. 
 
344 A definite correlation between C. jejuni LOS locus class prevalence and sequence type (STs) 
345 distribution has not been established yet due to the diverse population structure of C. jejuni (Habib et 
346 al., 2009; Islam et al., 2014). A few studies have shown concordance between specific STs and LOS 
347 classes. For example, LOS class B possessing GBS (50%) and enteritis (25%) C. jejuni isolates had 
348 ST-403 CC (Islam et al., 2009). Another study assigned class B diarrheal C. jejuni strains (3%) with 
349 ST-206 CC (Habib et al., 2009). LOS class C was associated with ST-21 CC in 14% of C. jejuni 
350 enteritis isolates (Revez and Hänninen, 2012), 11.2% of C. jejuni bacteraemia isolates (Ellström et al., 
351 2013), and 3.2% of diarrheal C. jejuni isolates (Habib et al., 2009). High frequency of LOS locus class 
352 C may be a contributor to the high predominance of clinical C. jejuni strains with ST-21 CC (Habib et 
353 al., 2009; Thépault et al., 2018). This ST-21 CC has also been found in LOS class A positive 
354 bacteraemia (2.8%) and diarrheal C. jejuni (0.4%) isolates (Habib et al., 2009; Ellström et al., 2013, 
355 Ohishi et al., 2017), which might be due to the close phylogenetic relationship between C. jejuni 
356 isolates with LOS classes A and C (Gilbert et al., 2008). LOS group 2 classes (E, H, O, and P) are 
357 associated with ST-677 CC and ST-45 CC in C. jejuni bacteraemia isolates (Ellström et al., 2013). 
358 However, another study found two other STs (ST-353 CC; ST-443 CC) for LOS group 2 related 





359 diarrheal C. jejuni strains in addition to ST-45 CC (Habib et al., 2009). Group 3 LOS class D have 
360 diarrheal C. jejuni strains (5%) that were assigned with ST-354 CC (Habib et al., 2009). 
361 
362 7. Concluding remarks 
 
363 This review extends the C. jejuni LOS locus classification system. Currently, genomic based 
364 classification of the LOS region is incomplete and vague . By providing a more refined classification 
365 system, investigators will be more readily able to link genomic class to LOS biosynthetic structures 
366 as they become available. Full LOS structural characterisation is currently limited, so it is hard to 
367 determine whether locus classes will readily align with LOS structures and is clearly a focus for future 
368 research and may aid vaccine design. We also provide an overview of the frequency of C. jejuni LOS 
369 genotypes in C. jejuni populations originated from different sources and reviews the association 
370 between C. jejuni LOS locus genotypes and different human ganglioside-mimicking sialylated LOS 
371 structures. This review summarises the various contributing factors in GBS development post 
372 Campylobacter infection and shows that LOS group 1 containing LOS locus classes A, B, and C are 
373 commonly present in almost every type of C. jejuni population studied to date, regardless of its 













380 Table 1. Variable LOS structures synthesised by different C. jejuni LOS locus types 
 
381 Experimentally characterized LOS structures to date. Hypothetical structures are not included here. 
382 Glycans in LOS structures were drawn according to the Symbol Nomenclature For Glycans (SNFG). 
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680 Figure legends 
 
681 Figure 1: A summary of the different host-pathogen factors that contribute to the complexity of 
682 GBS development. 
 
683   Figure 2: A representation of C. jejuni 11168 LOS core biosynthesis gene cluster and its LOS   
684 structure. Each arrow represents an individual LOS core biosynthesis gene and its direction indicates 
685 the direction of gene transcription. A LOS biosynthesis gene in yellow encodes an enzyme to catalyse 
686 the addition of a KDO molecule to lipid A. LOS biosynthesis genes in light pink encode enzymes for 
687  the synthesis of LOS inner core structure. LOS biosynthesis genes in green encode enzymes for the   
688 synthesis of LOS outer core structure; where LOS genes in light green (neuB1, neuC1 and cgtA/neuA1) 
689 synthesise sialic acid to incorporate into the outer core. LOS genes in white (gmhA, waaE, waaD, and 
690   gmhB) synthesise heptoses for inner core. Glycan structures were drawn  according to the Symbol    
691 Nomenclature For Glycans (SNFG). 
 
692 Figure 3: Simplified C. jejuni LOS locus classification system. LOS classes are classified into the  
693    previously established four groups on the basis of sharing similar LOS biosynthesis gene content.    
694  Arrows in checked boxes: LOS biosynthesis gene content, shared between the classes within a LOS  
695 group; Blue arrows: Variable LOS biosynthesis genes, located between lgtF (orf3) and waaV (orf12); 
696 Pink arrows: LOS  biosynthesis genes, commonly present in  all  LOS  classes. Genes  are numbered 
697  according to the Parker et al. (2005) numbering system. Arrow direction represents the direction of   
698 gene transcription. 
 
699  Figure 4: A comparison of previous findings of distribution of C. jejuni LOS locus genotypes in  
700 various C. jejuni populations: ENT: C. jejuni isolates from enteritis patients; GBS: C. jejuni isolates 
701 from GBS patients; Chick: C. jejuni isolates from chicken. BB infection: C. jejuni isolates from patients 
702 with Blood Borne infections. 
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